Table 2 Patient, donor, and transplant characteristics according to conditioning regimen for patients included in the propensity score analysis.
FluTBI (n = 115) | FluTreo (n = 115) | P | |
|---|---|---|---|
Median patient age, years (range) | 55.2 (40.1–70.7) | 54.9 (40.4–74.9) | 0.96 |
Karnofsky performance score | |||
<90 | 26 (22.6%) | 27 (23.5%) | 0.88 |
>=90 | 89 (77.4%) | 88 (76.5%) | |
Diagnosis | |||
De novo AML | 100 (87%) | 100 (87%) | 1 |
Secondary AML | 15 (13%) | 15 (13%) | |
Cytogenetic risk group | |||
Good | 4 (4.5%) | 5 (6.5%) | |
Intermediate | 66 (75.0%) | 54 (70.1%) | |
Poor | 18 (20.5%) | 18 (23.4%) | |
NA/failed | 27 | 38 | |
Not adverse | 97 (84.3%) | 97 (84.3%) | 1 |
Adverse | 18 (15.7%) | 18 (15.7%) | |
FLT3 ITD | |||
Negative | 65 (77.4%) | 50 (67.6%) | 0.17 |
Positive | 19 (22.6%) | 24 (32.4%) | |
Missing | 31 | 41 | |
NPM1 | |||
Wildtype | 64 (76.2%) | 50 (67.6%) | 0.39 |
Mutated | 20 (23.8%) | 21 (30%) | |
Missing | 31 | 45 | |
Median interval from diagnosis to HSCT, months (range) | 3.8 (1.8–16.2) | 4.5 (1.7–16.2) | 0.15 |
Median year of HSCT (range) | 2014 (2009–2019) | 2016 (2009–2019) | 0.005 |
MRD status pre-transplant | |||
MRD negative | 37 (61.7%) | 30 (58.8%) | 0.76 |
MRD positive | 23 (38.3%) | 21 (41.2%) | |
Missing | 55 | 64 | |
Donor | |||
Matched sibling | 71 (61.7%) | 71 (61.7%) | 1 |
10/10 HLA matched unrelated | 44 (38.3%) | 44 (38.3%) | |
Patient sex | |||
Male | 68 (59.1%) | 64 (55.7%) | 0.59 |
Female | 47 (40.9%) | 51 (44.3%) | |
Donor/patient sex | 70 (60.9%) | 71 (61.7%) | 0.89 |
Female/male | 22 (19.1%) | 20 (17.4%) | 0.73 |
Other combinations | 93 (80.9%) | 95 (82.6%) | |
Donor/patient CMV status | |||
Donor negative/patient positive | 27 (24.3%) | 28 (24.6%) | 0.97 |
Other combinations | 84 (75.7%) | 86 (75.4%) | |
Missing | 4 | 1 | |
TBI fractions | NA | ||
4 × 2 Gy | 33 (28.7%) | ||
2 × 4 Gy | 15 (13.0%) | ||
unknown | 67 (58.3%) | ||
Treosulfan dose | NA | ||
3 × 10 g/m2 | 27 (23.5%) | ||
3 × 12 g/m2 | 23 (20.0%) | ||
3 × 14 g/m2 | 65 (56.5%) | ||
In vivo T-cell depletion | |||
No | 60 (52.2%) | 62 (53.9%) | 0.79 |
ATG | 55 (47.8%) | 53 (46.1%) | |
GVHD prevention | |||
Cyclosporin A + MTX | 98 (85.2%) | 85 (73.9%) | 0.08 |
Cyclosporin A + MMF | 10 (8.7%) | 21 (18.3%) | |
Other | 7 (6.1%) | 9 (7.8%) | |
Median follow-up, months [95% CI] | 42.37 [31.52–53.77] | 23.2 [20.44–32.74] | 0.14 |
